NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Forecast, Price & News $7.66 +0.19 (+2.54%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$7.37▼$7.7350-Day Range$6.41▼$9.5852-Week Range$3.46▼$9.82Volume465,760 shsAverage Volume568,062 shsMarket Capitalization$387.21 millionP/E RatioN/ADividend YieldN/APrice Target$26.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Marinus Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside243.2% Upside$26.29 Price TargetShort InterestHealthy3.62% of Shares Sold ShortDividend StrengthN/ASustainability-1.53Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.80) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector259th out of 981 stocksPharmaceutical Preparations Industry118th out of 462 stocks 3.5 Analyst's Opinion Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.29, Marinus Pharmaceuticals has a forecasted upside of 243.2% from its current price of $7.66.Amount of Analyst CoverageMarinus Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.62% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently increased by 19.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarinus Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Epilepsy medication (N03)", "Clinical research services for Epilepsy or seizures", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marinus Pharmaceuticals is -1.53. Previous Next 1.9 News and Social Media Coverage News SentimentMarinus Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.Search InterestOnly 18 people have searched for MRNS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.86% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions86.88% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($2.80) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -12.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -12.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarinus Pharmaceuticals has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Marinus Pharmaceuticals (NASDAQ:MRNS) StockMarinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.Read More Receive MRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MRNS Stock News HeadlinesMay 30, 2023 | msn.comJMP Securities Reiterates Marinus Pharmaceuticals (MRNS) Market Outperform RecommendationMay 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Marinus (MRNS) and Iovance Biotherapeutics (IOVA)June 7, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 26, 2023 | finance.yahoo.comMarinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency DisorderMay 24, 2023 | americanbankingnews.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $26.29 Average Target Price from BrokeragesMay 19, 2023 | americanbankingnews.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Forecasted to Post FY2023 Earnings of ($2.35) Per ShareMay 17, 2023 | finance.yahoo.comMarinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.May 16, 2023 | finance.yahoo.comAnalyst Forecasts For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging HigherJune 7, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 15, 2023 | americanbankingnews.comTruist Financial Cuts Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target to $42.00May 13, 2023 | msn.comTruist Securities Maintains Marinus Pharmaceuticals (MRNS) Buy RecommendationMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Marinus Pharmaceuticals (MRNS) Buy RecommendationMay 12, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Marinus (MRNS)May 10, 2023 | msn.comMarinus Pharmaceuticals Q1 2023 Earnings PreviewMay 9, 2023 | americanbankingnews.comMarinus Pharmaceuticals (MRNS) Scheduled to Post Earnings on ThursdayMay 8, 2023 | americanbankingnews.comCritical Review: Marinus Pharmaceuticals (NASDAQ:MRNS) versus DiaMedica Therapeutics (NASDAQ:DMAC)May 4, 2023 | finance.yahoo.comEarnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to DeclineApril 29, 2023 | americanbankingnews.comMarinus Pharmaceuticals, Inc. to Post FY2025 Earnings of ($2.02) Per Share, Oppenheimer Forecasts (NASDAQ:MRNS)April 27, 2023 | finance.yahoo.comMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023April 27, 2023 | americanbankingnews.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $24.29 Average Price Target from AnalystsApril 25, 2023 | msn.comOppenheimer Maintains Marinus Pharmaceuticals (MRNS) Outperform RecommendationApril 21, 2023 | americanbankingnews.comShort Interest in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Increases By 17.1%April 18, 2023 | finance.yahoo.comMarinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price Matching Investor OpinionApril 18, 2023 | finance.yahoo.comMarinus Pharmaceuticals (MRNS) Stock Jumps 8.4%: Will It Continue to Soar?April 18, 2023 | finance.yahoo.comMarinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of DirectorsApril 17, 2023 | msn.comUnusual Call Option Trade in Marinus Pharmaceuticals (MRNS) Worth $131.32KApril 4, 2023 | americanbankingnews.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $24.29 Consensus Target Price from BrokeragesSee More Headlines MRNS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRNS Company Calendar Last Earnings11/09/2021Today6/06/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees113Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.29 High Stock Price Forecast$42.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+243.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,820,000.00 Net Margins-169.99% Pretax Margin-146.71% Return on Equity-179.11% Return on Assets-62.35% Debt Debt-to-Equity Ratio1.26 Current Ratio10.23 Quick Ratio10.22 Sales & Book Value Annual Sales$25.48 million Price / Sales15.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book3.39Miscellaneous Outstanding Shares50,550,000Free Float48,091,000Market Cap$387.21 million OptionableOptionable Beta1.15 Key ExecutivesScott N. BraunsteinChairman, President & Chief Executive OfficerSteven E. PfanstielChief Operating Officer, CFO & TreasurerJoseph HulihanChief Medical OfficerMichael S. SaporitoVice President-ResearchMartha E. ManningSecretary, Senior Vice President & General CounselKey CompetitorsEntrada TherapeuticsNASDAQ:TRDAOmerosNASDAQ:OMERscPharmaceuticalsNASDAQ:SCPHKhosla Ventures AcquisitionNASDAQ:KVSAOculisNASDAQ:OCSView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 29,494 shares on 5/16/2023Ownership: 0.885%State Street CorpBought 9,900 shares on 5/16/2023Ownership: 0.301%Susquehanna International Group LLPSold 19,700 shares on 5/16/2023Ownership: 0.000%Graham Capital Management L.P.Bought 78,063 shares on 5/16/2023Ownership: 0.154%Balyasny Asset Management L.P.Bought 17,423 shares on 5/16/2023Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions MRNS Stock - Frequently Asked Questions Should I buy or sell Marinus Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRNS shares. View MRNS analyst ratings or view top-rated stocks. What is Marinus Pharmaceuticals' stock price forecast for 2023? 6 brokerages have issued 1 year price objectives for Marinus Pharmaceuticals' shares. Their MRNS share price forecasts range from $18.00 to $42.00. On average, they anticipate the company's stock price to reach $26.29 in the next year. This suggests a possible upside of 243.2% from the stock's current price. View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts. How have MRNS shares performed in 2023? Marinus Pharmaceuticals' stock was trading at $3.98 at the beginning of 2023. Since then, MRNS stock has increased by 92.5% and is now trading at $7.66. View the best growth stocks for 2023 here. Are investors shorting Marinus Pharmaceuticals? Marinus Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,830,000 shares, an increase of 19.6% from the April 30th total of 1,530,000 shares. Based on an average trading volume of 630,600 shares, the short-interest ratio is currently 2.9 days. View Marinus Pharmaceuticals' Short Interest. When is Marinus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our MRNS earnings forecast. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.23. The biopharmaceutical company had revenue of $10.11 million for the quarter, compared to analyst estimates of $2.32 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 179.11% and a negative net margin of 169.99%. During the same quarter in the prior year, the business earned ($0.51) EPS. What ETFs hold Marinus Pharmaceuticals' stock? ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), iShares Biotechnology ETF (IBB), When did Marinus Pharmaceuticals' stock split? Marinus Pharmaceuticals's stock reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO). What is Marinus Pharmaceuticals' stock symbol? Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS." Who are Marinus Pharmaceuticals' major shareholders? Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Suvretta Capital Management LLC (9.56%), AIGH Capital Management LLC (2.64%), GMT Capital Corp (2.38%), BlackRock Inc. (2.27%), Franklin Resources Inc. (2.07%) and Assenagon Asset Management S.A. (1.37%). View institutional ownership trends. How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Marinus Pharmaceuticals' stock price today? One share of MRNS stock can currently be purchased for approximately $7.66. How much money does Marinus Pharmaceuticals make? Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $387.21 million and generates $25.48 million in revenue each year. The biopharmaceutical company earns $-19,820,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. How many employees does Marinus Pharmaceuticals have? The company employs 113 workers across the globe. How can I contact Marinus Pharmaceuticals? Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565. This page (NASDAQ:MRNS) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.